Erectile dysfunction in patients with diabetes mellitus: results of epidemiological monitoring

Aim. Screening for erectile dysfunction (ED) in patients with type 1 and 2 diabetes mellitus. Materials and methods. The study included 611 patients with type 1 (n=276) and 2 (n=335) diabetes mellitus. The control group comprised 70 patients.The methods used were a questionnaire survey, HbA1c measurement, evaluation of renal and cardiovascular function, examination of ocularfundus, lower extremities and genital organs. Differences were considered significant at p

Download Full-text

Clinical and Dynamic Range-of-Motion Techniques in Subjects With and Without Diabetes Mellitus

Journal of the American Podiatric Medical Association ◽

10.7547/87507315-92-3-136 ◽

2002 ◽

Vol 92 (3) ◽

pp. 136-142 ◽

Cited By ~ 7

Author(s):

Paul Tinley ◽

Michael Taranto

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Range Of Motion ◽

Dynamic Range ◽

Control Group ◽

Limited Joint Mobility ◽

Study Results ◽

Patients With Diabetes ◽

Female Subjects

Thirty subjects with type 1 diabetes, 30 subjects with type 2 diabetes, and 30 age- and sex-matched controls were evaluated through clinical goniometry and two-dimensional motion analysis systems to determine the dynamic and static range of motion of the knee, ankle, and hallux joints. The purpose of this study was to determine if the knee and ankle joints of patients with diabetes mellitus are affected by limited joint mobility syndrome. The study results support previous medical literature showing significant reduction of range of motion of the hallux in subjects with type 1 diabetes. Significant differences were found between the range of motion of male and female subjects in all lower-limb joints for both subject groups with diabetes compared to the control group, and male subjects in all groups recorded less range of motion than female subjects. (J Am Podiatr Med Assoc 92(3): 136-142, 2002)

Download Full-text

Predictors of Early Retinal Changes in Diabetes Mellitus

Ophthalmology in Russia ◽

10.18008/1816-5095-2020-1-88-95 ◽

2020 ◽

Vol 17 (1) ◽

pp. 88-95

Author(s):

V. S. Kulybysheva ◽

I. A. Ronzina ◽

A. A. Gamidov ◽

V. G. Motalov ◽

V. N. Nikolenko

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Dynamic Control ◽

Clinical Manifestations ◽

Light Sensitivity ◽

Control Group ◽

Patients With Diabetes ◽

Almost All

Purpose. Determining the functional state of the outer and inner retina’s layers in patients with diabetes mellitus (DM) type 1 and 2 before the clinical manifestations and in the early stages of diabetic retinopathy (DR) using the methods of multifocal electroretinography (mfERG) and microperimetry (MP).Patients and methods. 91 patients were examined (182 eyes). The patients were divided into 4 groups: 1st — 23 people (46 eyes) with diabetes without DR (the duration of the disease is up to 2 years); 2nd — 22 people (44 eyes) with diabetes without DR (diabetes from 2 to 8 years); 3rd — 24 people (48 eyes) with NPDR on the background of diabetes; 4th — 22 people (44 eyes) of the control group (healthy eyes). In addition to the standard ophthalmologic examination, all patients were registered mfERG (FOK1) on the diagnostic equipment EP-1000 Multifocal (Tomey, Germany) and carried out MP using the device “MAIA” (CenterVue, Italy).Results. According to mfERG, it has been established that the components of mfERG, the biopotential density and the amplitude of P1, are most sensitive to diabetic changes. In groups with type 1 and type 2 diabetes, there is a significant decrease in the density of P1 in comparison with the control group (p < 0.005, Mann-Whitney test), as well as a decrease in the amplitude of P1 on almost all tested rings (p < 0.005). In all groups, there is an increase in the latency of P1 in the central ring (0–2.3°). According to MP data, it was found that patients with type 1 and type 2 diabetes showed a decrease in the average light sensitivity in comparison with the control group, however, our data are within the reference values, regardless of the presence or absence of clinical manifestations of PD.Conclusion. As a result of the study, early functional and morphological disorders of the neurosensory apparatus of the eye in diabetes were identified. It is proved that mfER and MP allow to detect violations at the preclinical stage of DR and are necessary studies for the dynamic control of the progression of DR.

Download Full-text

Renal dysfunction markers in patients with diabetes mellitus type 1 after kidney or simultaneous kidney-pancreas transplantation

Problems of Endocrinology ◽

10.14341/probl201662514-16 ◽

2016 ◽

Vol 62 (5) ◽

pp. 14-16

Author(s):

Alexandra M. Glazunova ◽

Larisa V. Nikankina ◽

Alexandr V. Ilin ◽

Minara S. Shamkhalova ◽

Gulya M. Musaeva ◽

...

Keyword(s):

Diabetes Mellitus ◽

Renal Transplant ◽

Renal Dysfunction ◽

Cystatin C ◽

Pancreas Transplantation ◽

Diabetes Mellitus Type 1 ◽

Diabetes Mellitus Type ◽

Control Group ◽

Patients With Diabetes

Objective. To examine kidney transplant dysfunction markers in patients with diabetes mellitus type 1 (T1DM) after kidney transplantation (KT) and simultaneous kidney-pancreas transplantation (SPK).Materials and methods. The study included 20 patients after successful SPK (group 1) and 41 patients after KT (21 received insulin pump therapy (group 2), 20 –multiple daily injections of insulin (group 3). Post transplantation period at the time of inclusion in the KT group was 8 months [7;8], in SPK-11 months [8;18]. The control group consisted of 15 patients with DM1 without diabetic nephropathy (group 4). Sex, age and duration of T1DM were comparable. Donors of SPK were younger than KT: 29 [25; 33] vs 46[30; 51] years p<0,01 and transplant cold ischemia time was less 8[7;10] vs 11,5 [1; 17] hours respectively, p<0,01. After 9 months of observation biomarkers of dysfunction of renal transplant: Cystatin C (serum, urine); NGAL, KIM-1, podocin, nephrin, IL-18, IP-10 (urine), TGF-β1, MMP-9, VEGF-A, Osteopontin – (OPN) (serum) were defined.Results. the level of GFR in patients after transplantation was C2 stage, albuminuria A1 of chronic kidney disease. In the group of patients with T1DM after successful SPK and KT revealed a significant increase in markers of renal dysfunction (cystatin C (serum), NGAL, Podocin, OPN) compared with the control group despite of carbohydrate metabolism compensation (Tabl.1). High level and a negative associated of blood cystatin C with GFR (r = - 0,36, p<0.05) and positive with albuminuria (r=0,40, p<0,05), as well as a direct link of podocin urine-with blood creatinine (r = 0,35, p<0.05) and NGAL with albuminuria (r = 0,35, p<0.05) in recipients after transplantation were defined. Association between podocin with MMP-9 (r = 0,46, p<0,05) and NGAL (r = 0,33, p<0,05) indicated correlation of stress factors of renal microstructures in posttransplantation patients.Conclusion. High levels of renal graft dysfunction biomarkers in the examined patients (including those after SPK) show the persistence of damage to the microstructures with stable graft function and demonstrate the need to control all factors in the preservation of renal function.Table 1. Renal transplant dysfunction markersParametrsGroup 1Group 2Group 3Group 4TGF b1 (serum, pg/ml)32999[24514;3917]24473[21752;33330]25139[11367;2862]26986[17347;4266]VEGF A (serum, pg/ml)471,9[296;530,6]#407,6[301,6;522,2] #226,6[177,8;367,4]467,4[288,3;474,8]CYS C, (serum, ng/ml)1047[985;1295]*∞1252,9[1151;1540]#∞1113,32[986;1257] §728,8[592,9;765,3]Osteopontin (serum, ng/ml)3,51[2,7;4,9] #∞4,28[2,8;8,2] ∞4,71[3,6;12,7] §2,86[2,2;3,1]MMP-9 (urine, ng/ml)1,15[1,1;1,7]1,30[1,2;1,9] #1,10[0,9;1,3]1,22[1,0;1,3]IP-10 (urine, ng/ml)17,83[17,32;18,36]17,83[17,32;18,36]18,36[17,83;18,90]18,36[17,83;18,90]CYS C (urine, ng/ml)10407[5812;16306]15574[7518;28397]13329[7006;24624]14701[3643;26666]Podocin (urine, ng/ml)0,41[0,18;0,51] #0,49[0,26;0,69]0,56[0,38;0,79]§0,36[0,1;0,51]Nephrin (urine, ng/ml)0,0[0,0;0,1]0,0[0,0;01]0,0[0,0;0,07]0,07[0,0;0,1]KIM-1 (urine, ng/ml)211,8[83,3;368,4]314,9[152,1;508,6]338,7[191,3;594,0]359,2[204,4;494,5]NGAL (urine, ng/ml)2,4[1,7;6,7] *7,8[2,8;14,5] ∞2,9[1,8;12,0]§2,3[1,7;7,3]* р<0,01 (1-2); # р<0,01 (1,2-3); ∞ р<0,01 (1,2-4); § р<0,01 (3–4)

Download Full-text

Etiological features of bacterial keratitis in patients with diabetes mellitus

Archive of Ukrainian Ophthalmology ◽

10.22141/2309-8147.9.1.2021.229518 ◽

2021 ◽

Vol 9 (1) ◽

pp. 10-13

Author(s):

O.V. Zavoloka

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Type 1 Diabetes Mellitus ◽

Causative Agent ◽

Staphylococcus Epidermidis ◽

Control Group ◽

Bacterial Keratitis ◽

Gram Positive ◽

Patients With Diabetes

Background. The purpose was to study etiological features of bacterial keratitis in patients with type 1 diabetes mellitus. Materials and methods. The analysis was performed on the basis of survey data of 62 patients with bacterial keratitis and type 1 diabetes mellitus and 43 individuals with bacterial keratitis without diabetes mellitus of the corresponding age (control group). In addition to standard ones, ophthalmic methods included fluorescein test, anterior segment optical coherence tomography, non-contact corneal aesthesiometry, bacteriological examination: culture from the conjunctival cavity to dense nutrient media (5% blood agar and medium for sterility control), microscopic examination of conjunctival smear with Romanowsky-Giemsa and Pappenheim stain. Results. Etiological features of bacterial keratitis were found in patients with diabetes mellitus: Gram-positive microflora was the causative agent 1.5 times more often, and Gram-negative — 3.1 times less often than in patients without diabetes mellitus from the control group (p < 0.05). In addition, Staphylococcus epidermidis was the causative agent of bacterial keratitis in patients with diabetes mellitus 1.9 times more often, and Pseudomonas aeruginosa — 6.3 times less often than in patients of the control group (p < 0.05). Conclusions. There are etiological features of bacterial keratitis in patients with diabetes mellitus, namely predominance of the Gram-positive microflora among the pathogens due to Staphylococcus epidermidis.

Download Full-text

The use of phosphodiesterase type 5 (pde-5) inhibitors in treatment of erectile dysfunction in patients with diabetes mellitus of different age groups

Kazan medical journal ◽

10.17816/kmj1451 ◽

2014 ◽

Vol 95 (1) ◽

pp. 31-35

Author(s):

T V Mehtiyev

Keyword(s):

Diabetes Mellitus ◽

Erectile Dysfunction ◽

Rating Scale ◽

Age Groups ◽

Control Group ◽

Type I ◽

Male Hypogonadism ◽

Phosphodiesterase Type 5 Inhibitors ◽

Patients With Diabetes ◽

Phosphodiesterase Type

Aim. To study the effect of phosphodiesterase type 5 inhibitors used to treat the erectile dysfunction in patients of different age groups with concomitant diabetes mellitus. Methods. The study included 293 patients with diabetes mellitus type I and II aged 17-60 years, with duration of diabetes varying from 6 months to 29 years, duration of erectile dysfunction - from 6 months to 12 years. To diagnose the erectile dysfunction, an international index of erectile function, together with routine and special methods were used. Patients were administered phosphodiesterase type 5 inhibitors: sildenafil, taladafil and vardenafil. The control group included men with the erectile dysfunction without diabetes. To identify the male hypogonadism, patients were examined depending on the age group: 18-29 years, 30-39 years, 40-49 years, 50-59 years. Patiens were tested for sex hormones level, male ageing questionnaires were administered. Results. The increased rate of hypogonadism (from 12.5 to 54%) was associated with older age in patients with diabetes mellitus. The androgen status index in patients with diabetes mellitus, according to the Aging Males’ Symptoms rating scale, was 37.1±1.4 points. Phosphodiesterase type 5 inhibitors were more effective in younger age groups (57.1-91.7%) compared to older (36.8-67.3%). When comparing the study drugs, vardenafil showed better effect and relatively few side effects. Conclusion. Androgen deficiency, developing with increasing age is accompanied by a decrease in phosphodiesterase type 5 inhibitors efficiency. The use of small doses of these drugs corresponding the circadian rhythm of testosterone in males with normal testosterone blood level has the same effect as large doses.

Download Full-text

Immunohystochemical study of the largest islets of human pancreas in aging and diabetes mellitus: perspectives for the transplantation

Diabetes Mellitus ◽

10.14341/dm2013438-43 ◽

2013 ◽

Vol 16 (4) ◽

pp. 38-43

Author(s):

Alexandra Evgen'evna Proshchina ◽

Yulia Sergeevna Krivova ◽

Valeriy Mikhaylovich Barabanov ◽

Sergey Vyacheslavovich Savelyev

Keyword(s):

Diabetes Mellitus ◽

Pancreatic Islets ◽

Age Groups ◽

Diabetes Mellitus Type 1 ◽

Pancreatic Tissue ◽

Control Group ◽

Human Pancreas ◽

Patients With Diabetes ◽

The Rich

Aim. To study the distribution and cellular architecture of the largest human pancreatic islets (with a diameter of more than 200 micron) in aging and diabetes mellitus types 1 and 2. Materials and methods. Antibodies to insulin, glucagon, somastatin and nturon-specific enolase were applied. The autopsy samples of the pancreatic tissue of patients with diabetes mellitus type 1 (DMT1) and type 2 (DMT2) and 2 age groups (up to 50 years old (control) and after 50 (aging control)), not suffering from diseases of the pancreas and carbohydrate metabolism malfunction were investigated. Results. The number of islets with diameter more than 200 mkm compared to control group increased both in aging and diabetes groups. Their number reaches in some cases 15% (and higher in DM) of the total number of islets. These islets compared to the other are rich-vascularized. It was shown that glucagon and somatostatin-containing cells are found both on the periphery of the large islets, and inside them only in the immediate proximity of the capillaries. Insulin-containing cells form clusters, surrounded by the capillaries and the ?- and ?-cells, while the inner part of such clusters has no direct contact with the capillaries. In the large islets the number of glucagon-containing cells is often increased, and insulin-containing cells show signs of degradation. Conclusion. The largest of the pancreatic islets may be useless for the transplantation, because of the high content of glucagon-containing cells, the rich vascularization and, in some cases, the limited functionality of ?-cells.

Download Full-text

Effect of tadalafil on erectile dysfunction in male patients with diabetes mellitus

Vojnosanitetski pregled ◽

10.2298/vsp0706399p ◽

2007 ◽

Vol 64 (6) ◽

pp. 399-404 ◽

Cited By ~ 5

Author(s):

Srdjan Popovic ◽

Djordje Nale ◽

Marija Dabetic ◽

Dragana Matanovic ◽

Vesna Dimitrijevic-Sreckovic ◽

...

Keyword(s):

Diabetes Mellitus ◽

Erectile Dysfunction ◽

Type 2 Dm ◽

Patients With Diabetes ◽

Male Patients ◽

Group 2 ◽

Group 1 ◽

Diabetes Patients

Background/Aim. During the first 10 years over 50% of diabetes patients develop erectile dysfunction (ED). It is more severe and resistant to therapy than in male patients with normal glucoregulation. The purpose of this pilot study was to estimate the tadalafil (Cialis) efficacy and safety in male patients with diabetes mellitus (DM), together with moderate to severe ED. Methods. The study included 30 male patients with diagnozed type 1 or type 2 DM together with ED. ED was estimated through the International Index of Erectile Function (IIEF-6), Sexual Encounter Profile (SEP) questionnaire and prostaglandin test, at the beginning of the research and three months after the 20 mg tadalafil therapy initiation, once a week (on Fridays). Glycosylated haemoglobin in blood (HbA1c) values were also monitored. According to the ED severity (IIEF values at the beginning of the therapy) the patients were divided into 2 groups. The previous experience with sildenafil citrate (Viagra) and prostaglandin E1 intracavernous therapy was recorded. Results. Tadalafil significantly improved ED (p < 0.001) for 7.40 points of the IIEF score, i.e. for 58% and 60% towards SEP2 and SEP3 questionnaire, respectively. Compared to the previous ED therapy subjectively better tadalafil experience was recorded. Each group experienced a significant improvement in IIEF score (p < 0.001), more significantly in the group 2 (8.26?1.49 points) compared with the medium improvement in the group 1 (6.27?1.35 points). After three months HbA1c values decreased for 2.26?1.62 (p < 0.001). Conclusion. Tadalafil is an effective tool for treating ED in diabetes patients. In some situations tadalafil application could replace prostaglandin test. The sexual sphere motivation leads to the improvement of glucoregulation in DM patients. .

Download Full-text

Erectile dysfunction as a manifestation of urogenital autonomic neuropathy in patients with type 1 diabetes: epidemiology, classification, pathophysiology, diagnosis and treatment options

Diabetes Mellitus ◽

10.14341/dm20142126-132 ◽

2014 ◽

Vol 17 (2) ◽

pp. 126-132

Author(s):

Gagik Radikovich Galstyan ◽

Yana Grigor'evna Shwarts ◽

Sergey Anatol'evich Dubsky ◽

Alexander Evgen'evich Lepetukhin ◽

Roman Viktorovich Rozhivanov ◽

...

Keyword(s):

Quality Of Life ◽

Diabetes Mellitus ◽

Erectile Dysfunction ◽

Social Life ◽

Treatment Options ◽

Significant Decline ◽

Sexual Disorder ◽

Patients With Diabetes

Sexual dysfunction characterized by a significant decline in the quality of life of patients and leading to infertility and problems in social life is diagnosed in more than 40% of patients with diabetes mellitus (DM). Erectile dysfunction is the most common sexual disorder in DM patients. The article describes epidemiology, classification, pathophysiology, diagnostic and treatment of erectile dysfunction in T1DM patients.

Download Full-text

Estimation of Vascular Cell Adhesion Molecule 1 (VCAM-1) Levels In Type 1 Diabetic Mellitus Patients

Bionatura ◽

10.21931/rb/2021.06.04.26 ◽

2021 ◽

Vol 6 (4) ◽

pp. 2292-2294

Author(s):

Ousamha Akram Saterr ◽

Abeer J. Hassan ◽

Qahtan Adnan Rasheed

Keyword(s):

Diabetes Mellitus ◽

Cardiovascular Disease ◽

Microvascular Complications ◽

Fasting Blood Glucose ◽

Control Group ◽

Diabetic Patients ◽

Insulin Levels ◽

Significant Difference ◽

Patients With Diabetes

High glucose levels in patients with diabetes are associated with increased plasma levels of soluble adhesion molecules. They could explain that the patients with diabetes mellitus will require the development of premature atherosclerosis related to hyperglycemia or hyperinsulinemia and that it not only affects vascular endothelium but also contributes to the development of microvascular complications. This study aimed to evaluate the serum concentration of VCAM-1 in type 1 diabetes mellitus patients with and without cardiovascular disease. Also, investigation the association of insulin levels, duration of diabetes, and HbA1C with VCAM-1. Include in this study a total of 60 types 1 diabetic patient. According to characteristic laboratory investigations and electrocardiogram (ECG), they were subdivided into two groups (G1) 30 T1DM patients without cardiovascular disease and (G2) 30 T1DM patients with cardiovascular disease in addition to 30 healthy subjects as a control group (G3). All subjects measured the levels of fasting blood glucose FBG, glycated hemoglobin HbA1c, and insulin levels, and VCAM-1 were also determined by ELISA technique. This study shows a highly significant difference in the average diabetic profile between G1 and G2 compared to the control group and found that VCAM-1 level was significantly higher among diabetic patients than the control group. Also, there was a significant negative correlation of VCAM-1 with the levels of FBG, HbA1c in diabetic patients G1 and G2. While insulin had a positive correlation in G1 but correlated negatively in G2

Download Full-text

The influence of para-aminobenzoic acid on the inflammatory process in dry eye disease in patients with diabetes mellitus (clinical and laboratory research)

POINT OF VIEW EAST – WEST ◽

10.25276/2410-1257-2021-2-19-23 ◽

2021 ◽

pp. 19-23

Author(s):

A.A. Ryabtseva ◽

◽

G.K. Ali-Zade ◽

S.I. Akberova ◽

O.V. Moskalets ◽

...

Keyword(s):

Diabetes Mellitus ◽

Dry Eye ◽

Dry Eye Disease ◽

Eye Disease ◽

Enzyme Linked Immunosorbent Assay ◽

Control Group ◽

Eye Drops ◽

Patients With Diabetes

Purpose. Study of the effect of 0.007% PABA solution in the form of the drug Aktipol-M on the inflammatory process based on the assessment of the level of sIL-6R and NE in the lacrimal fluid (LF), with dry eye disease (DED) in patients with diabetes mellitus (DM). Material and methods. The study involved 30 patients (60 eyes) with type 1 and 2 diabetes, aged 35 to 70 years, with a diagnosis of DED. Patients received Aktipol-M eye drops for one month. The contents of NE (10 patients, 20 eyes) and sIL-6R (20 patients, 40 eyes) were determined in the LF. The control group consisted of 10 healthy volunteers (20 eyes). Quantitative determination of the content of sIL-6R and NE was carried out by the method of enzyme-linked immunosorbent assay. Thirty patients (60 eyes) with type 1 and 2 diabetes, aged 35 to 70 years, with a diagnosis of DED were examined. The patients received Aktipol-M eye drops for one month. The content of NE (10 patients, 20 eyes) and sIL-6R (20 patients, 40 eyes) was determined in the LF. The control group consisted of 10 healthy volunteers (20 eyes). The quantitative determination of the content of sIL-6R and NE was carried out by the method of enzyme-linked immunosorbent assay. Results. The patients showed a higher content of sIL-6R (10974.8±1228.5 pkg/ml) and NE (3.85 ± 0.13 ng / ml) compared with the control group (4.6 ± 0.7 pkg / ml and 0.22 ± 0.08 ng/ml, respectively). After 1 month after the start of treatment, a significant decrease in these parameters was observed in all patients and in both eyes: on average, the content of sIL-6R by 80.5% and the NE content by 58.7%. Conclusion. PABA 0.007% in the dosage form of eye drops Aktipol-M has an anti-inflammatory effect, suppressing the production of sIL-6R and NE in the LF in DED in patients with diabetes. Key words: para-aminobenzoic acid, dry eye disease, diabetes mellitus, inflammation, neutrophilic elastase, soluble interleukin-6 receptor.

Download Full-text